Related Experiment Video
Updated: May 26, 2026

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
Published on: January 20, 2019
Effect of ribavirin on junin virus infection in guinea pigs
M Salazar1, N E Yun, A L Poussard
1Galveston National Laboratory and Institute for Human Infections and Immunity, Department of Pathology, Sealy Vaccine Center, University of Texas Medical Branch, Galveston, TX, USA.
Abstract:
Junin virus (JUNV) is the aetiological agent of Argentine haemorrhagic fever. The pathogenesis of the infection is not well understood, no licensed vaccines exist and no specific antiviral therapy is available. Previous studies have demonstrated the ability of ribavirin to delay and reduce JUNV disease and virus burden in guinea pigs without preventing death. Based on available data, we performed three different studies to determine the efficacy of ribavirin against JUNV in the guinea pig model with a focus on survival. Different doses and treatment schedules of ribavirin were tested in a lethal model of JUNV infection. Our results show that prolonged treatment with high doses of ribavirin significantly reduces the mortality in guinea pigs infected with JUNV. These results may be useful in future experimental studies or clinical testing.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Cytomegalovirus Disease
Subviral Agents
Retroviruses
Arboviral Encephalitis

